TABLE 2.
Study outcomes by the treatment groups in the matched cohort.
| Overall | Empagliflozin | Linagliptin | p-value | |||
|---|---|---|---|---|---|---|
| (n = 7,042) | (n = 3,521) | (n = 3,521) | ||||
| AKI, n (%) | 211 | 67 | (1.9) | 144 | (4.1) | <0.001 |
| Incidence rate (per 1,000 person-years) | 14.3 | 27.5 | ||||
| AKI stage, n (%) | ||||||
| 1 | 128 | 42 | (1.2) | 86 | (2.4) | |
| 2 | 20 | 7 | (0.2) | 13 | (0.4) | |
| 3 | 63 | 18 | (0.5) | 45 | (1.3) | |
| Dialysis-acquiring AKI, n (%) | 35 | 9 | (0.3) | 26 | (0.7) | 0.004 |
| Deaths with AKI, n (%) | 36 | 5 | (0.1) | 31 | (0.9) | 0.001 |
| Deaths for any cause, n (%) | 89 | 23 | (0.7) | 66 | (1.9) | <0.001 |
| eGFR decline changes from baseline (ml/min/1.73 m2 per year) | ||||||
| Median (25th, 75th) | 2.4 | (−3.9, 9.9) | 2.8 | (−2.9, 9.6) | 0.058 | |
AKI: acute kidney injury; eGFR: estimated glomerular filtration rate. Standardized mean difference (SMD) < 0.10 indicating no significant difference in baseline covariates between two treatment groups.